{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '8.2', 'Secondary Objectives', 'The secondary objectives (analyzed hierarchically) are:', '1. Evaluate the effect of teprotumumab versus placebo on the overall responder rate', '(percentage of subjects with > 2-point reduction in CAS AND > 2 mm reduction in', 'proptosis from Baseline, provided there is no corresponding deterioration [> 2 point/mm', 'increase] in CAS or proptosis in the fellow eye) at Week 24.', '2. Evaluate the effect of teprotumumab versus placebo on the percentage of subjects with a', 'CAS value of 0 or 1 at Week 24 in the study eye.', '3. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', 'Week 24 in proptosis measurement in the study eye.', '4. Evaluate the effect of teprotumumab versus placebo on the diplopia responder rate (i.e.,', 'the percentage of subjects with baseline diplopia > 0 in study eye who have a reduction of', '> 1 grade with no corresponding deterioration D 1 grade worsening] in', 'the', 'fellow', 'eye)', 'at', 'Week 24.', '5. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', \"Week 24 in the Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire overall\", 'score.', '8.3', 'Exploratory Objectives', 'The exploratory objectives are:', '1. Evaluate the effect of teprotumumab versus placebo on the Clinical Measures of Severity', 'individual response status frequencies and percentage of responders for each component', 'of clinical severity from Baseline to Week 24.', '2. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', 'Week 24 in the CAS.', '3. Evaluate the effect of teprotumumab versus placebo on the overall responder rate at', 'Week 24 stratified by the level of response (high responders, responders, low responders,', 'and non-responders; see Section 9.6.4.3.1 for definitions).', '4. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure and', 'understand PK-PD relationships.', '5.', 'Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', 'Week 24 in the GO-QoL questionnaire visual functioning (VF) and appearance (A)', 'subscale scores.', '6. Evaluate the effect of teprotumumab on the mean change from Baseline to Week 24 in', 'blood and serum biomarkers.', '7. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', 'Week 24 on the motility component of the Clinical Measures of Severity.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 63 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9', 'INVESTIGATIONAL PLAN', '9.1', 'Overall Study Design and Plan', 'This study will be conducted at up to 16 sites in the United States and Europe.', 'This is a randomized, double-masked, placebo-controlled, parallel-group, multicenter study.', 'Subjects will be screened for the study within 2 to 6 weeks prior to the Baseline (Day 1) Visit.', 'Approximately 76 subjects (38/group) who meet the study eligibility criteria will be randomized', 'on Day 1 in a 1:1 ratio (stratified by tobacco use status) to receive 8 infusions of teprotumumab', '(10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) or placebo every', '3 weeks (q3W). All subjects will enter a 24-week double-masked Treatment Period, during', 'which study drug will be infused on Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21', '(with a final visit at Week 24). All study drug dosing will be performed at the clinic under the', 'supervision of clinic staff, and at any scheduled infusion, the infusion rate may be reduced or the', 'dose may be interrupted or held based on decreased tolerability (see Section 9.4.6.3.2 for', 'details). On each dosing day, scheduled assessments (except for AE and concomitant medication', 'use monitoring, which will be monitored throughout the clinic visit) will be completed prior to', 'study drug dosing. After each of the first 2 infusions, subjects will be contacted by phone/email', 'the following day and will return to the clinic 1 week after the infusion (Weeks 1 and 4) for', 'safety and tolerability assessments; additional phone/email contacts and clinic visits may also be', 'conducted for any subject experiencing an infusion-associated event.', 'At the end of the double-masked Treatment Period (Week 24), subjects who are proptosis', 'non-responders (study eye has < 2 mm decrease in proptosis) will be eligible to enter an', 'open-label extension study (HZNP-TEP-302) in which subjects may receive 8 infusions of', 'teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) in an', 'open-label fashion. Discussion of this option with the subject and informed consent presentation', 'for HZNP-TEP-302 should be discussed at the Week 24 Visit given enrollment in HZNP-TEP-', '302 must occur within 2 weeks of the Week 24 Visit.', 'At Week 24, proptosis responders, as well as non-responders who choose not to enroll in the', 'open-label extension study (HZNP-TEP-302), will enter a 48-week Follow-Up Period, during', 'which study drug will not be administered and clinic visits are scheduled for Weeks 28, 36, 48,', '60, and 72 (Months 7, 9, 12, 15, and 18). Subjects who are responders at Week 24 but who meet', 'the criteria for re-treatment due to a relapse during the Follow-Up Period may enroll in the', 'open-label extension study, HZNP-TEP-302 (see Section 9.3.4 for details).', 'Subjects who prematurely discontinue study drug dosing prior to Week 21 of the Treatment', 'Period will return to the clinic and undergo the scheduled Week 24 assessments and will be', 'encouraged to participate in the Follow-Up Period unless they initiated another intervention due', 'to lack of efficacy. Subjects who enter the Follow-Up Period but prematurely discontinue study', 'participation prior to 48 weeks following the double-masked Treatment Period will return for a', 'final visit and undergo the scheduled Week 72 assessments prior to study discharge.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 64 of 117']\n\n###\n\n", "completion": "END"}